autologous CD7-CAR T cells

Autologous CD7-CAR T cells represent a cutting-edge cell therapy where a patient's own T lymphocytes are genetically engineered to express a Chimeric Antigen Receptor (CAR) specifically designed to recognize and bind to the CD7 protein. CD7 is a transmembrane glycoprotein highly expressed on the surface of malignant T cells in various hematological cancers, including T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) and a subset of acute myeloid leukemia (AML). A significant challenge in developing CD7-targeted CAR T cells is the phenomenon of "fratricide," where the CAR T cells, which also naturally express CD7, would attack and kill each other. This issue is typically overcome through advanced gene-editing techniques, such as CRISPR/Cas9, to knock out the endogenous CD7 expression on the engineered T cells, or by using protein expression blockers or natural selection strategies. Once engineered and expanded, these modified T cells are infused back into the patient, where they proliferate, identify, and eliminate CD7-expressing cancer cells, offering a potent immunotherapy approach for relapsed or refractory malignancies.

Other names

anti-CD7 CAR-T cellsanti-CD-7 CAR-T cellsanti-CD 7 CAR-T cellsCD7-targeted autologous CAR-T cellsCD-7-targeted autologous CAR-T cellsCD 7-targeted autologous CAR-T cells